Nippon Shinyaku takes on Sarepta
A new competitor enters the exon 53 skipping niche, and might well take it over.
The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
Sanofi’s third Translate collaboration sees big bucks at last
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
Inclisiran keeps on giving
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
Astrazeneca throws Silence an $80m lifeline
Silence has received an important validation, but making progress could be tough.
Upcoming events – Gilead’s Nash refocus and an early chance for Ionis and Roche
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
Novartis bets $9.7bn on RNA interference
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Speedy nod sets Alnylam up for its second launch
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
